Correction to: Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

被引：0
|
作者：
Gwan Gyu Song
Young Ho Lee
机构：
[1] Korea University College of Medicine,Department of Rheumatology
[2] Korea University Anam Hospital,Division of Rheumatology, Department of Internal Medicine
[3] Korea University College of Medicine,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original version of this article unfortunately contained a mistake. The corresponding author was incorrect.
引用
收藏
页码：701 / 701
相关论文
共 50 条
  • [41] Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
    Eder, Lihi
    Gladman, Dafna
    Aydin, Sibel
    Ogdie, Alexis
    Shi, Harry
    Landry, Pierre-Alexandre
    Luna, Rayana
    [J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1043 - 1044
  • [42] Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis A Bayesian network meta-analysis of randomized controlled trials
    Bae, S. -C.
    Lee, Y. H.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (05): : 421 - 428
  • [43] Safety and efficacy characteristics of oral drugs in patients with premature ejaculation: a Bayesian network meta-analysis of randomized controlled trials
    Qin, Zhiqiang
    Wang, Yi
    Zhu, Jundong
    Zhu, Kai
    Li, Ran
    Zhang, Lei
    Meng, Xianghu
    Xia, Jiadong
    Wang, Wei
    Qin, Chao
    Zhang, Wei
    Song, Ninghong
    Wang, Zengjun
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2019, 31 (05) : 356 - 368
  • [44] Safety and efficacy characteristics of oral drugs in patients with premature ejaculation: a Bayesian network meta-analysis of randomized controlled trials
    Zhiqiang Qin
    Yi Wang
    Jundong Zhu
    Kai Zhu
    Ran Li
    Lei Zhang
    Xianghu Meng
    Jiadong Xia
    Wei Wang
    Chao Qin
    Wei Zhang
    Ninghong Song
    Zengjun Wang
    [J]. International Journal of Impotence Research, 2019, 31 : 356 - 368
  • [45] NETWORK META-ANALYSIS OF TOFACITINIB VS BDMARDS OR APREMILAST FOR THE TREATMENT OF TNF INHIBITOR-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS
    Gladman, D. D.
    Orbai, A. -M.
    Gomez-Reino, J.
    Chang-Douglass, S.
    Leoncini, E.
    Burton, H. E.
    Kanik, K. S.
    Hendrikx, T.
    Cappelleri, J. C.
    Hsu, M. -A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 368 - 369
  • [46] Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
    Castro, Adela
    Diaz, Jesus
    Quiceno, Guillermo
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [47] Comparison of the efficacy among different interventions for radiodermatitis: A Bayesian network meta-analysis of randomized controlled trials
    Guan, Ying
    Liu, Shuai
    Li, Anchuan
    Cheng, Wanqin
    [J]. PLOS ONE, 2024, 19 (04):
  • [48] Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials
    Sung, Yoon-Kyoung
    Lee, Young Ho
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (01) : 13 - 23
  • [49] Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials
    Xiaojing Huang
    Haojie Shentu
    Yujing He
    Haijia Lai
    Chen Xu
    Meiling Chen
    Haowei Zhu
    [J]. Immunologic Research, 2023, 71 : 505 - 515
  • [50] Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials
    Huang, Xiaojing
    Shentu, Haojie
    He, Yujing
    Lai, Haijia
    Xu, Chen
    Chen, Meiling
    Zhu, Haowei
    [J]. IMMUNOLOGIC RESEARCH, 2023, 71 (04) : 505 - 515
12345